

IN THE SPECIFICATION

On page 1, add the following section between the title and “Field of the Invention”:

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a national phase application filed under 35 U.S.C. § 371 of PCT Application Number PCT/US2004/022817, filed July 15, 2004, which claims priority from U.S. Provisional Patent Application Number 60/489,402, filed July 23, 2003.

In the table on pages 19-21, in the 3rd column, replace the word “cylated” with the words “% Acylated”.

Formulation D2		
100 mM NaOAc (pH 4)		
Day	% Peptide Released	<u>evlated</u> % Acylated Peptide Released
0	0.0	0.0
1	5.55	0.15
3	13.75	0.78
6	53.47	4.11
10	71.74	5.16
14	72.19	5.26
20	72.21	5.28
24	72.22	5.30
29	72.22	5.30
34	72.22	5.30
42	72.22	5.30
48	72.22	5.30

Formulation D2		
PBS (pH 7)		
Day	% Peptide Released	<u>acylated</u> % Acylated Peptide Released
0	0.0	0.0
1	1.81	0.08
3	3.09	0.22
6	4.87	0.59
10	7.54	1.98
14	10.42	4.29
20	17.81	10.51
24	20.69	14.06
29	23.86	18.86
34	26.21	23.12
42	32.91	28.73
48	35.13	32.14
57	36.50	35.10
64	37.83	37.41
71	38.42	45.82
78	38.58	46.37
85	38.64	46.70

Formulation AG		
PBS (pH 7)		
Day	% Peptide Released	<u>eylated</u> % Acylated Peptide Released
0	0.0	0.0
1	8.04	0.33
2	9.09	0.47
6	12.27	0.65
15	17.75	1.23
24	20.03	1.78
29	23.78	2.66
35	36.16	5.62
42	43.80	8.15
49	51.17	11.13
57	61.47	15.57
64	67.63	18.16